aflibercept 8 mg
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV)
Trial Timeline
Dec 24, 2026 → Dec 1, 2028
NCT ID
NCT07389980About aflibercept 8 mg
aflibercept 8 mg is a phase 3 stage product being developed by Bayer for Polypoidal Choroidal Vasculopathy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07389980. Target conditions include Polypoidal Choroidal Vasculopathy, Polypoidal Choroidal Vasculopathy (PCV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07389980 | Phase 3 | Recruiting |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Intravitreal aflibercept injection 2.0mg | Regeneron Pharmaceuticals | Approved | 84 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 82 |
| aflibercept | Bayer | Approved | 82 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 25 |